相似文献
1
Primary thrombocytosis in children.
Haematologica. 2014 Apr;99(4):620-8. doi: 10.3324/haematol.2013.092684.
2
Contemporary management of essential thrombocythemia in children.
Expert Rev Hematol. 2019 May;12(5):367-373. doi: 10.1080/17474086.2019.1602034. Epub 2019 Apr 27.
3
Thrombocytosis and thrombocythemia.
Blood Rev. 2001 Dec;15(4):159-66. doi: 10.1054/blre.2001.0162.
4
Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Am J Hematol. 2015 Feb;90(2):162-73. doi: 10.1002/ajh.23895.
5
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Ann Hematol. 2021 Jul;100(7):1647-1665. doi: 10.1007/s00277-021-04485-0. Epub 2021 Mar 12.
6
[Diagnostic workup in front of an adult thrombocytosis].
Ann Biol Clin (Paris). 2021 Oct 1;79(5):415-425. doi: 10.1684/abc.2021.1671.
7
[Thrombocytosis and thrombocythemia].
Rev Med Interne. 1985 Jun;6(3):285-90. doi: 10.1016/s0248-8663(85)80119-3.
8
Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.
Int J Hematol. 2012 Dec;96(6):810-3. doi: 10.1007/s12185-012-1193-8. Epub 2012 Oct 7.
9
Thrombocythemia and polycythemia in patients younger than 20 years at diagnosis: clinical and biologic features, treatment, and long-term outcome.
Blood. 2012 Mar 8;119(10):2219-27. doi: 10.1182/blood-2011-08-371328. Epub 2012 Jan 18.
10
Essential thrombocythaemia.
Best Pract Res Clin Haematol. 2006;19(3):439-53. doi: 10.1016/j.beha.2005.07.004.
引用本文的文献
1
Childhood and adolescent essential thrombocythemia and prefibrotic primary myelofibrosis: insights into diagnosis, outcomes, and treatment from a large Chinese cohort.
Leukemia. 2025 Jan;39(1):155-165. doi: 10.1038/s41375-024-02432-2. Epub 2024 Oct 8.
2
Etiology and clinical course of severe and extreme thrombocytosis in children: a retrospective single-center study.
Eur J Pediatr. 2024 Nov;183(11):4783-4788. doi: 10.1007/s00431-024-05755-5. Epub 2024 Sep 4.
3
Stuttering priapism in a pediatric patient with pheochromocytoma-induced thrombocytosis.
Urol Ann. 2022 Jul-Sep;14(3):283-287. doi: 10.4103/ua.ua_118_21. Epub 2022 Jul 18.
4
Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey.
EJHaem. 2020 Jun 27;1(1):86-93. doi: 10.1002/jha2.39. eCollection 2020 Jul.
5
Essential Thrombocythemia in Children and Adolescents.
Cancers (Basel). 2021 Dec 6;13(23):6147. doi: 10.3390/cancers13236147.
6
Essential Thrombocythemia in a 15-Year-Old Female: Presentation, Workup, and Treatment Considerations in the Pediatric Population.
J Adv Pract Oncol. 2021 May;12(4):423-429. doi: 10.6004/jadpro.2021.12.4.6. Epub 2021 May 1.
7
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Ann Hematol. 2021 Jul;100(7):1647-1665. doi: 10.1007/s00277-021-04485-0. Epub 2021 Mar 12.
8
Extreme thrombocytosis is associated with critical illness and young age, but not increased thrombotic risk, in hospitalized pediatric patients.
J Thromb Haemost. 2020 Dec;18(12):3352-3358. doi: 10.1111/jth.15103. Epub 2020 Oct 21.
9
Clinical course and short-term outcome of postsplenectomy reactive thrombocytosis in children without myeloproliferative disorders: A single institutional experience from a developing country.
PLoS One. 2020 Aug 5;15(8):e0237016. doi: 10.1371/journal.pone.0237016. eCollection 2020.
10
Myeloproliferative Neoplasms in Children, Adolescents, and Young Adults.
Curr Hematol Malig Rep. 2020 Apr;15(2):141-148. doi: 10.1007/s11899-020-00571-8.
本文引用的文献
1
Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
N Engl J Med. 2013 Dec 19;369(25):2391-2405. doi: 10.1056/NEJMoa1312542. Epub 2013 Dec 10.
2
Somatic mutations of calreticulin in myeloproliferative neoplasms.
N Engl J Med. 2013 Dec 19;369(25):2379-90. doi: 10.1056/NEJMoa1311347. Epub 2013 Dec 10.
3
JAK Inhibitors and other Novel Agents in Myeloproliferative Neoplasms: Are We Hitting the Target?
Ther Adv Hematol. 2011 Aug;2(4):203-11. doi: 10.1177/2040620711410095.
4
Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial.
Blood. 2013 Mar 7;121(10):1720-8. doi: 10.1182/blood-2012-07-443770. Epub 2013 Jan 11.
5
Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.
Int J Hematol. 2012 Dec;96(6):810-3. doi: 10.1007/s12185-012-1193-8. Epub 2012 Oct 7.
6
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis).
Blood. 2012 Dec 20;120(26):5128-33; quiz 5252. doi: 10.1182/blood-2012-07-444067. Epub 2012 Oct 1.
7
Impact of hydroxyurea on clinical events in the BABY HUG trial.
Blood. 2012 Nov 22;120(22):4304-10; quiz 4448. doi: 10.1182/blood-2012-03-419879. Epub 2012 Aug 22.
8
Front-line therapy in polycythemia vera and essential thrombocythemia.
Blood Rev. 2012 Sep;26(5):205-11. doi: 10.1016/j.blre.2012.06.002. Epub 2012 Jul 10.
9
Germline JAK2 mutation in a family with hereditary thrombocytosis.
N Engl J Med. 2012 Mar 8;366(10):967-9. doi: 10.1056/NEJMc1200349.
10
A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia.
Am J Hematol. 2012 May;87(5):532-4. doi: 10.1002/ajh.23138. Epub 2012 Mar 3.
Zotero 插件